❌

Reading view

Divide-and-Conquer Inference for Large-Scale Visual Recognition with Multimodal Large Language Models

arXiv:2605.24799v1 Announce Type: cross Abstract: Multimodal Large Language Models (MLLMs) have demonstrated strong capabilities across a wide range of vision language tasks. However, when applied to large scale image classification, their performance degrades significantly as the label space expands a phenomenon we define as Performance Collapse in Long Sequence Recognition. Through an information theoretic analysis, we reveal that this collapse stems from a fundamental conflict between the escalating information entropy and the prominent attention dilution and decay within attention mechanisms, which impairs the model's ability to maintain a sufficient signal-to-noise ratio when processing extremely long prompts. To mitigate this, we propose Divide-and-Conquer Inference (DCI), a novel test-time scaling strategy for visual recognition with MLLMs. DCI recursively decomposes complex global classification tasks into multiple simpler, localized subproblems and employs a dynamic pruning mechanism to compress the search space. This method effectively improves the local signal to noise ratio and model accuracy by mitigating the inherent weight dilution issues in long-sequence inference. Moreover, while traditional self-attention incurs a prohibitive quadratic computational complexity, DCI achieves more favorable scaling behavior and substantially accelerates inference in large scale classification scenarios. Extensive experiments on benchmarks such as ImageNet-1K and ImageNet-21K demonstrate that DCI consistently improves classification accuracy. This enables lightweight open-source models to rival or even surpass frontier closed-source giants without any additional training or fine-tuning. As a model-agnostic, plug-and-play paradigm, DCI offers an efficient approach for scaling the inferential precision of MLLMs in large-scale scenarios.
  •  

Subspace-Guided Semantic and Topological Invariant Registration for Annotation-Free Ultrasound Plane Quality Control

arXiv:2605.25396v1 Announce Type: cross Abstract: Reliable quality control (QC) of ultrasound images is essential for both real-time acquisition guidance and retrospective clinical audit, yet existing approaches rely heavily on per-plane annotations, or employ pseudo-labeling prone to systematic bias under spatial deformations inherent in clinical acquisition. We present STRIQ, a registration-driven framework that recasts annotation-free US plane quality control as a subspace-guided consistency measurement problem. Specifically, STRIQ introduces a Latent Registration Aligner (LRA) to establish hierarchical feature space correspondences between query images and variance-driven anchors, which are autonomously distilled from unlabeled data via a variance spectrum criterion to serve as structurally stable prototypes. To further disambiguate anatomical planes and mitigate negative knowledge transfer, we propose an Orthogonal Knowledge Subspace (OKS) module. The OKS decomposes plane-specific representations into mutually orthogonal subspaces, enabling fine-grained expert collaboration while preventing inter-plane interference, ensuring that the quality metric is grounded in principled subspace proximity. Extensive experiments on the in-house US4QA and public CAMUS datasets demonstrate that STRIQ achieves state-of-the-art correlation with clinical quality scores, establishing a new paradigm for annotation-free, real-time reliable ultrasound quality control. Our code is available at https://github.com/zhcz328/STRIQ.
  •  

Anatomy-Anchored Self-Supervision: Distilling Vision Foundation Models for Invariant Ultrasound Representation

arXiv:2605.25402v1 Announce Type: cross Abstract: Self-supervised pre-training paradigm has gained increasing prominence for learning transferable representations in medical imaging, yet existing methods for ultrasound (US) images operate at the image or frame level, overlooking the anatomical context for clinical-aligned representation learning. In this work, we propose an anatomy-anchored ultrasound self-supervision framework ANAUS that shifts representation learning from generic visual regions to clinically meaningful anatomical structures. Utilizing a learnable latent prompt engine alongside a one-time domain adaptation on existing public image--mask pairs, we empower the LP-SAM module to achieve annotation-free anatomy delineation at scale. Building upon this anatomical grounding, we propose a dual-policy self-supervised learning paradigm consisting of inter-view semantics-aware anatomy-separating alignment and contextual core-region prediction to enhance representation learning. Specifically, the former enforces feature invariance within identical anatomical regions while promoting discriminability across distinct structures; the latter compels the model to reconstruct corrupted regions, thereby capturing fine-grained structural details. Extensive evaluations on six public datasets demonstrate that \ours{} consistently outstrips current state-of-the-art methods while maintaining the computational efficiency essential for clinical deployment. Code is available at https://github.com/zhcz328/ANAUS.
  •  

Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence

Drug Des Devel Ther. 2026 May 18;20:603491. doi: 10.2147/DDDT.S603491. eCollection 2026.

ABSTRACT

This review systematically summarizes the chemical composition, mechanisms of action, and recent progress in research and clinical applications of Yupingfeng San (YPFS) in various diseases. Research indicates that YPFS contains abundant active constituents-such as flavonoids, coumarins, and terpenoids, and demonstrates diverse biological activities,including immune modulation, anti-inflammatory, antiviral, antibacterial, and antitumor activities. Recent pharmacological and network pharmacology studies have elucidated that YPFS regulates key signaling pathways - such as PI3K-Akt, NF-ΞΊB, TLR4/MyD88, and JAK-STAT - through multi-target and multi-pathway mechanisms. These effects contribute to its therapeutic role in allergic rhinitis (AR), asthma, atopic dermatitis (AD), liver cancer, lung cancer, and other conditions. Although limited clinical trials and meta-analyses suggest that YPFS, when combined with conventional therapies, can improve treatment efficacy, relieve symptoms, and demonstrate good safety and tolerability, current research is constrained by low evidence quality and the absence of standardized quality control measures. Future research should prioritize large-scale, multi-center clinical trials and integrate multi-omics approaches to identify the main active components and mechanisms of action.

PMID:42182585 | PMC:PMC13196821 | DOI:10.2147/DDDT.S603491

  •  

Advances in Yupingfeng San Research: Multi-Target Mechanisms and Clinical Evidence

Drug Des Devel Ther. 2026 May 18;20:603491. doi: 10.2147/DDDT.S603491. eCollection 2026.

ABSTRACT

This review systematically summarizes the chemical composition, mechanisms of action, and recent progress in research and clinical applications of Yupingfeng San (YPFS) in various diseases. Research indicates that YPFS contains abundant active constituents-such as flavonoids, coumarins, and terpenoids, and demonstrates diverse biological activities,including immune modulation, anti-inflammatory, antiviral, antibacterial, and antitumor activities. Recent pharmacological and network pharmacology studies have elucidated that YPFS regulates key signaling pathways - such as PI3K-Akt, NF-ΞΊB, TLR4/MyD88, and JAK-STAT - through multi-target and multi-pathway mechanisms. These effects contribute to its therapeutic role in allergic rhinitis (AR), asthma, atopic dermatitis (AD), liver cancer, lung cancer, and other conditions. Although limited clinical trials and meta-analyses suggest that YPFS, when combined with conventional therapies, can improve treatment efficacy, relieve symptoms, and demonstrate good safety and tolerability, current research is constrained by low evidence quality and the absence of standardized quality control measures. Future research should prioritize large-scale, multi-center clinical trials and integrate multi-omics approaches to identify the main active components and mechanisms of action.

PMID:42182585 | PMC:PMC13196821 | DOI:10.2147/DDDT.S603491

  •  

Targeted Therapy-Induced Interstitial Lung Disease in NSCLC: Mechanisms, Clinical Signatures, and a Precision Medicine Roadmap

Drug Des Devel Ther. 2026 Apr 8;20:600434. doi: 10.2147/DDDT.S600434. eCollection 2026.

ABSTRACT

Molecularly targeted therapies have transformed the therapeutic landscape of non-small cell lung cancer (NSCLC), establishing precision oncology as the foundation of modern disease management. However, these advances are increasingly complicated by drug-induced interstitial lung disease (DILD), a potentially life-threatening adverse event that can disrupt treatment continuity and compromise clinical benefit. In this review, we provide a comprehensive evaluation of interstitial lung disease associated with targeted agents in NSCLC, including oncogene-directed tyrosine kinase inhibitors, antibody-drug conjugates (ADCs), and angiogenesis inhibitors. We summarize reported differences in ILD incidence, onset timing, clinical manifestations, and radiographic characteristics across targeted agents, with particular emphasis on high-risk populations and the elevated ILD incidence observed with deruxtecan-based ADCs. We further summarize current mechanistic evidence suggesting that DILD may arise from multiple overlapping processes, including immune-mediated inflammatory activation, direct epithelial cytotoxicity, off-target kinase inhibition, and payload-dependent bystander injury. Finally, we discuss current challenges and future directions for improving pulmonary safety, including real-world datasets, multi-omics approaches, and emerging AI-assisted tools for earlier detection and risk stratification. Importantly, the current evidence base remains limited by the predominance of retrospective studies, case reports, and incomplete mechanistic validation. These insights may help guide safer and more sustained implementation of targeted therapies in NSCLC.

PMID:41978697 | PMC:PMC13070417 | DOI:10.2147/DDDT.S600434

  •  
❌